Tag Archive for: Sofinnova Partners

Trends in life science investments – Top take-aways from Anglonordic

The first panel of the day, chaired by Mary Clark, our co-founder and CEO, saw a group of Europe’s leading investors – Hakan Goker, M Ventures; Maina Bhaman, Sofinnova Partners; Christian Elling, Lundbeckfonden; and Roel Bulthuis, Syncona – share sage advice for companies looking to raise funds, providing insights on the most important factors shaping […]

#Biotech: How to Thrive in 2023’s Precision Financing World

Melanie Senior’s article in Nature Portfolio on ‘Precision Financing’ highlights the rigour behind private biotech financing in 2023 where strong data and efficiency are essential. Two of our clients, Naveed Siddiqi of Novo Holdings and Antoine Papiernik from Sofinnova Partners were featured. Here are some key takeaways… Since the pandemic, the biotech industry has experienced […]

Bloomberg’s insight on the challenges facing the UK’s life sciences sector

Following Jeremy Hunt’s 2023 budget delivered earlier this month, in which he paved the way for faster access to new drugs and revealed R&D tax credits for life sciences companies, Bloomberg looked at the many challenges still facing the UK’s life sciences sector. Despite the success of the Oxford Covid-19 vaccine, the UK is still […]

Scrip Asks… What does 2023 hold for Biopharma?

More than one hundred industry executives and experts provided insight into what to expect for the year ahead. Here’s what we’ve read so far… Technological Advances Today’s article explores the technological advances expected during 2023. Developments in data science and molecular biology drive expectations – for another year of breakthrough innovation in human therapeutics. However, […]

Financing growth: Walking the tightrope – Annual Healthcare Investor Conference Insight

Financing growth: Walking the tightrope InsightIn the context of the particularly difficult public markets we have seen recently, Hannah Kuchler, Global Pharmaceuticals Correspondent at the Financial Times, chaired a panel of experts exploring what sources of capital are currently available to fund innovation and the development of new drugs, and what is needed to access […]